We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. is one of the top performers on Thursday.
Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.5630 apiece as investors cheered a national coverage agreement with UnitedHealth Group Inc.
Under the partnership, Plus Therapeutics Inc., through its subsidiary CNSide Diagnostics LLC, will provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT) to over 51 million people in the US.
Romaset/Shutterstock.com
The deal could translate into higher revenues for CNSide and Plus Therapeutics Inc..
The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.
According to Plus Therapeutics Inc., more than 11,000 CNSide tests have been performed at more than 120,000 cancer institutions since 2020, delivering high sensitivity and specificity of 92 percent and 95 percent, respectively, while influencing treatment decisions in 90 percent of cases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
Hedge Fund Resource Center